Jonathan William Sturm

Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s Disease Patients

Stephen Macfarlane, Timo Grimmer, Ken GW Teo, Terence John O'Brien et autres

Abstract IMPORTANCE There are no approved oral disease-modifying treatments for Alzheimer’s disease (AD) with the ability to prolong time in a stable disease state and with clinically meaningful outcomes clear to patients and caregivers. DESIGN The Phase IIb/III ANAVEX2-73-AD-004 study was a …

gb, de, au, us, Togo, ie, rs, ca, fr (code pays fourni par la source)

Prevention of Adverse Cardiovascular Events Using the 23-Valent Pneumococcal Polysaccharide Vaccine

Alexis Jayne Hure, Roseanne Peel, Catherine Anne D’Este, Walter P. Abhayaratna et autres

Importance: Animal studies and meta-analysis of human observational data suggest that pneumococcal polysaccharide vaccination (PPV) could be protective against atherosclerosis; however, to the authors' knowledge, no randomized clinical trial has been conducted. Objective: To determine whether pneumococcal vaccination (Pneumovax [Merck Sharp & …

au (code pays fourni par la source)

Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial

Stephen Macfarlane, Timo Grimmer, Ken GW Teo, Terence John O'Brien et autres

BACKGROUND: There are no approved oral disease-modifying treatments for Alzheimer's disease (AD). OBJECTIVES: The objective of this study was to assess efficacy and safety of blarcamesine (ANAVEX®2-73), an orally available small-molecule activator of the sigma-1 receptor (SIGMAR1) in early AD through restoration …

au, de, gb, in, nl, ca, us (code pays fourni par la source)

Clinical Implementation of Disease Modifying Drugs for Alzheimer's Disease: The Australian and New Zealand Context

Amy G. Brodtmann, Christopher R S Belder, David Jakabek, Colin Mahoney et autres

au, us, kr, nz (code pays fourni par la source)

Analyzing and understanding the robustness of bioprocesses

Lucas Becker, Jonathan William Sturm, Frank Eiden, Dirk Holtmann

The robustness of bioprocesses is becoming increasingly important. The main driving forces of this development are, in particular, increasing demands on product purities as well as economic aspects. In general, bioprocesses exhibit extremely high complexity and variability. Biological systems often have a …

de (code pays fourni par la source)

2369 Young spinal stroke – ? Fibrocartilaginous embolism

Sai Adithya Nagaratnam, Raymond Lee, Jonathan William Sturm

Objectives Fibrocartilaginous embolism is a rarely reported cause of spinal cord infarction.1 The embolism arises from cartilaginous nucleus pulposus material entering the spinal cord vasculature usually after a Valsalva manoeuvre.2 Case A 36-year-old woman presented with sudden onset bilateral arm paraesthesia and …

au (code pays fourni par la source)

Fibrocartilaginous embolism: an under-recognised cause of young spinal stroke

Sai Adithya Nagaratnam, Raymond Lam Kwong Lee, Jonathan William Sturm

Fibrocartilaginous embolism is a rarely reported cause of spinal cord infarction. Seemingly innocuous activities may be associated with nucleus pulposus material embolising to the spinal cord vasculature. We describe a 36-year-old woman presenting with bilateral arm paraesthesia and chest pain that evolved …

au (code pays fourni par la source)

Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial

Shu Ping Ren, Philip M. Hansbro, Wichat Srikusalanukul, Jay Christopher Horvat et autres

BACKGROUND AND AIMS: Observational studies have demonstrated that the pneumococcal polysaccharide vaccine (PPV) is associated with reduced risk of cardiovascular events. This may be mediated through IgM antibodies to OxLDL, which have previously been associated with cardioprotective effects. The Australian Study for …

au, us (code pays fourni par la source)

Case-Fatality and Functional Outcome after Subarachnoid Hemorrhage (SAH) in INternational STRoke oUtComes sTudy (INSTRUCT)

Sabah Rehman, Hoang Thi Phan, Mathew J. Reeves, Amanda Gay Thrift et autres

au, us, it, gr, nz, fr, br, pt, se, ee, ca, in, ir (code pays fourni par la source)

115 Erroneously normal active B12 level in a case of subacute combined degeneration of the cord

Nicholas Halliwell, Cecily J. Forsyth, Nicholas J. Taylor, Sarah Mangalasseril et autres

Objectives Vitamin B12 is crucial for neurologic function, red blood cell production, and DNA synthesis. Deficiency can lead to a wide spectrum of haematologic and neuropsychiatric disorders including subacute combined degeneration of the cord. This report presents a case of a 47 …

au (code pays fourni par la source)

045 Multiple cranial neuropathies in a patient with syphilitic meningitis

Melissa M Chu, Shejil Kumar, Jonathan William Sturm

Background Syphilis is increasing in prevalence in the community.1 2 Neurosyphilis has protean manifestations making recognition, diagnosis and early initiation of treatment challenging. Methods/Results We present a case of early syphilitic meningitis in a 37-year-old female presenting with multiple cranial neuropathies (V, …

au (code pays fourni par la source)

Subacute combined degeneration of the spinal cord due to pernicious anaemia with an erroneously normal active B12 level

Nicholas Halliwell, Cecily J. Forsyth, Nicholas J. Taylor, Sarah Mangalasseril et autres

au (code pays fourni par la source)